GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Long-Term Debt

Biogen (BSP:BIIB34) Long-Term Debt : R$31,323 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Long-Term Debt?

Biogen's Long-Term Debt for the quarter that ended in Mar. 2024 was R$31,323 Mil.

Biogen's quarterly Long-Term Debt declined from Sep. 2023 (R$33,516 Mil) to Dec. 2023 (R$33,261 Mil) and declined from Dec. 2023 (R$33,261 Mil) to Mar. 2024 (R$31,323 Mil).

Biogen's annual Long-Term Debt declined from Dec. 2021 (R$35,479 Mil) to Dec. 2022 (R$32,946 Mil) but then increased from Dec. 2022 (R$32,946 Mil) to Dec. 2023 (R$33,261 Mil).


Biogen Long-Term Debt Historical Data

The historical data trend for Biogen's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Long-Term Debt Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,301.97 38,205.57 35,478.84 32,946.36 33,260.82

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32,724.07 30,503.56 33,515.99 33,260.82 31,323.44

Biogen  (BSP:BIIB34) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Biogen Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Biogen's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines